Compare Gilead Sciences, Inc. (GILD) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wix.Com Ltd — how do they compare? Gilead Sciences, Inc. trades at $133.51 (market cap $163.51B), while Wix.Com Ltd trades at $52.62 (market cap $2.23B). The key difference: Gilead Sciences, Inc. is far larger — about 73.3× Wix.Com Ltd's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| GILD | WIX | |
|---|---|---|
Market Cap | $163.51B | $2.23B |
Sector | Health | Technology |
52-Week High | $155.80 | $184.24 |
52-Week Low | $108.22 | $40.43 |
Enterprise Value | $178.05B | $1.79B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Wix.com (WIX) trades at $52.71, up 0.57% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong revenue growth to $1.99B in 2025, though net income margin turned negative at -1.97%. Recent news highlights a significant stock decline of 27% in May 2026 following Q1 earnings miss and an unanticipated spike in operating expenses, prompting multiple law firm investigations into potential securities fraud.
The outlook is polarized: strong analyst consensus (67.5% Buy) with an $83.13 price target suggests significant upside, but near-term risks are elevated due to the Q1 earnings miss, ongoing legal investigations, and volatile cash flow trends. Revenue growth remains robust, but profitability challenges and negative shareholder equity create headwinds for sustained value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
